New study confirms the prognostic role of suPAR with high negative predictive value in the ED

Tue May 12 2020

Research by the Hellenic Sepsis Study Group confirms the significance of suPAR as a rule-out marker with high negative predictive value, concluding that suPAR levels under 4 ng/mL support a safe discharge decision after clinical evaluation. The Position Paper was published in  Infectious Diseases and Therapy by Velissaris D. et al.

In light of the accumulating evidence on the negative predictive value of soluble urokinase plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care medicine, emergency medicine, internal medicine and infectious diseases has framed a position statement on the role of suPAR in the screening of patients admitted to the emergency department.

The main content of this statement is that suPAR is a non-specific marker associated with a high negative predictive value for unfavourable outcomes;levels < 4 ng/mL indicate that it is safe to discharge the patient, whereas levels > 6 ng/mL are an alarming sign of risk for unfavourable outcomes.
The suPAR levels should always be interpreted in light of the patient’s history.

Early risk detection is the main purpose of personnel committed to the triage of patients admitted to the emergency department (ED) of all secondary and tertiary hospitals. Successful triage may affect final outcomes.

The difficulty to triage often increases when clinical signs and symptoms are subtle or unspecific. Therefore, the group decided to frame a position paper on the role of suPAR in the early detection of risk of unfavourable outcome for patients admitted to the ED.

The following statement regarding the utility of suPAR for patients admitted to the ED was made:

Read the paper by Velissaris D et al here
Infect Dis Ther
https://doi.org/10.1007/s40121-020-00301-w

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates